[go: up one dir, main page]

DE60021266D1 - Verwendungen von zusammensetzungen zur behandlung oder vermeidung von schlafstörungen mit sehr niedrigdosierten cyclobenzaprine - Google Patents

Verwendungen von zusammensetzungen zur behandlung oder vermeidung von schlafstörungen mit sehr niedrigdosierten cyclobenzaprine

Info

Publication number
DE60021266D1
DE60021266D1 DE60021266T DE60021266T DE60021266D1 DE 60021266 D1 DE60021266 D1 DE 60021266D1 DE 60021266 T DE60021266 T DE 60021266T DE 60021266 T DE60021266 T DE 60021266T DE 60021266 D1 DE60021266 D1 DE 60021266D1
Authority
DE
Germany
Prior art keywords
cyclobenzaprine
dosed
compositions
treating
low
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60021266T
Other languages
English (en)
Other versions
DE60021266T2 (de
Inventor
W Iglehart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Krele Pharmaceuticals Inc
Original Assignee
Vela Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vela Pharmaceuticals Inc filed Critical Vela Pharmaceuticals Inc
Publication of DE60021266D1 publication Critical patent/DE60021266D1/de
Application granted granted Critical
Publication of DE60021266T2 publication Critical patent/DE60021266T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60021266T 1999-08-13 2000-08-11 Verwendungen von Zusammensetzungen zur Behandlung oder Vorbeugung von Schlafstörungen unter Verwendung von sehr niedrigen Dosen von Cyclobenzaprin Expired - Lifetime DE60021266T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14888199P 1999-08-13 1999-08-13
US148881P 1999-08-13
PCT/US2000/022082 WO2001012175A1 (en) 1999-08-13 2000-08-11 Uses compositions for treating or preventing sleep disturbances using very low doses of cyclobenzaprine

Publications (2)

Publication Number Publication Date
DE60021266D1 true DE60021266D1 (de) 2005-08-18
DE60021266T2 DE60021266T2 (de) 2006-05-24

Family

ID=22527835

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60021266T Expired - Lifetime DE60021266T2 (de) 1999-08-13 2000-08-11 Verwendungen von Zusammensetzungen zur Behandlung oder Vorbeugung von Schlafstörungen unter Verwendung von sehr niedrigen Dosen von Cyclobenzaprin

Country Status (18)

Country Link
US (3) US6395788B1 (de)
EP (1) EP1202722B1 (de)
JP (1) JP2003506484A (de)
AR (1) AR025110A1 (de)
AT (1) ATE299369T1 (de)
AU (1) AU6635400A (de)
BR (1) BR0013017A (de)
CA (1) CA2380432A1 (de)
DE (1) DE60021266T2 (de)
ES (2) ES2192156B1 (de)
GB (1) GB2368522A (de)
HK (2) HK1047883A1 (de)
IL (1) IL147777A0 (de)
MX (1) MXPA02001569A (de)
NZ (1) NZ516749A (de)
PT (1) PT1202722E (de)
WO (1) WO2001012175A1 (de)
ZA (2) ZA200200619B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002537245A (ja) * 1999-02-18 2002-11-05 ノバルティス アクチエンゲゼルシャフト ５−ｈｔ３レセプターアンタゴニストの使用
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US6635675B2 (en) 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
GB0128674D0 (en) * 2001-11-30 2002-01-23 Boots Co Plc Treatment of sleep disorders and the like
GB0312425D0 (en) * 2003-05-30 2003-07-09 Boots Co Plc Use of a compound in the treatment of sleep disorders and the like,in providing refreshedness on waking and a method for the treatment of grogginess therewith
JP4578083B2 (ja) * 2003-09-30 2010-11-10 小林製薬株式会社 催眠剤組成物
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US20070087055A1 (en) * 2005-10-14 2007-04-19 David Jan Directly compressible extended release alprazolam formulation
EP2998288B1 (de) 2005-12-01 2022-08-24 ACADIA Pharmaceuticals Inc. Substituierte phenethylamine mit serotoninergischer und/oder norepinephrinergischer aktivität
CA2641821C (en) * 2006-02-16 2017-10-10 Imthera Medical, Inc. An rfid-based apparatus, system, and method for therapeutic treatment of a patient
US20100179215A1 (en) * 2006-05-19 2010-07-15 Somaxon Pharmaceuticals, Inc. Doxepin isomers and isomeric mixtures and methods of using the same to treat sleep disorders
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
DK2125698T3 (en) * 2007-03-15 2016-11-07 Auspex Pharmaceuticals Inc Deuterated d9-VENLAFAXINE
JP2011500143A (ja) * 2007-10-09 2011-01-06 イムセラ・メディカル・インコーポレーテッド 選択的刺激のための装置、システム、及び方法
EP2313091A4 (de) * 2008-07-14 2012-04-04 Univ Kingston Pharmazeutische zusammensetzungen mit ret-hemmern und verfahren zur behandlung von krebs
CA2738479C (en) 2008-10-09 2017-11-28 Imthera Medical, Inc. Method of stimulating a hypoglossal nerve for controlling the position of a patient's tongue
WO2010133961A1 (en) 2009-05-22 2010-11-25 Inventia Healthcare Private Limited Extended release compositions of cyclobenzaprine
BR112012010986A2 (pt) * 2009-11-10 2016-04-12 Imthera Medical Inc sistema para estimular um nervo hipoglosso para o controle da posição da língua de um paciente
PL2501234T3 (pl) * 2009-11-20 2018-01-31 Tonix Pharma Holdings Ltd Sposoby i kompozycje stosowane w leczeniu dolegliwości związanych z zespołem stresu pourazowego z użyciem cyklobenzapryny
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
US11998516B2 (en) * 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
ITMI20110558A1 (it) * 2011-04-06 2012-10-07 Campiglio Consulting Srl Composizione farmaceutica contenente ciclobenzaprina adatta alla somministrazione endonasale
US9346742B2 (en) * 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
CA3118913C (en) 2012-06-15 2024-04-30 Tonix Pharma Holdings Limited Compositions and methods for transmucosal absorption
US9636408B2 (en) 2013-03-15 2017-05-02 Tonix Pharma Holdings Limited Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
MY186047A (en) 2014-09-18 2021-06-17 Tonix Pharma Holdings Ltd Eutectic formulations of cyclobenzaprine hydrochloride
EP3651751A4 (de) 2017-07-13 2021-03-31 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprin-analoga und amitryptilen
MX2020006140A (es) * 2017-12-11 2020-08-13 Tonix Pharma Holdings Ltd Tratamiento con ciclobenzaprina para la agitacion, psicosis y deterioro cognitivo en la demencia y enfermedades neurodegenerativas.
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
BR112021003107A2 (pt) * 2018-08-20 2021-05-11 Tonix Pharma Holdings Limited métodos de tratamento de transtorno de estresse agudo e transtorno de estresse pós-traumático
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
WO2021207561A1 (en) * 2020-04-08 2021-10-14 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine treatment for sexual dysfunction
CA3202722A1 (en) 2020-11-20 2022-05-27 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine treatment for alcohol use disorder
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1339636A (en) * 1917-02-23 1920-05-11 Tulloch Thomas Gregorie Fluid-tight joint for steam-pipes and the like
GB859187A (en) 1958-11-25 1961-01-18 United States Borax Chem Method for preparing substituted tris amino boranes
CA958643A (en) 1970-07-07 1974-12-03 Frosst (Charles E.) And Co. Pharmaceutical compositions containing cyclobenzaprine
FR2121529A1 (en) * 1971-01-05 1972-08-25 Merck & Co Inc Compsns contg cyclobenzaprine and indomethacin - chlordiazepoxide, phenylbutazone oxyphenbutazone or corticosteroid
GB2368283A (en) * 1999-08-13 2002-05-01 Vela Pharmaceuticals Inc Cyclobenzaprine for treating generalized anxiety disorder and compositions thereof

Also Published As

Publication number Publication date
HK1047691B (en) 2006-05-12
US20010046988A1 (en) 2001-11-29
WO2001012175A8 (en) 2001-05-10
GB2368522A8 (en) 2002-06-13
NZ516749A (en) 2004-03-26
EP1202722B1 (de) 2005-07-13
MXPA02001569A (es) 2002-07-02
US20040029869A1 (en) 2004-02-12
WO2001012175A1 (en) 2001-02-22
ES2192156B1 (es) 2005-02-16
EP1202722A1 (de) 2002-05-08
HK1047883A1 (zh) 2003-03-14
HK1047691A1 (en) 2003-03-07
ZA200200619B (en) 2003-04-23
CA2380432A1 (en) 2001-02-22
US6541523B2 (en) 2003-04-01
ES2245944T3 (es) 2006-02-01
GB2368522A (en) 2002-05-08
US6395788B1 (en) 2002-05-28
ZA200200852B (en) 2003-07-30
PT1202722E (pt) 2005-11-30
ES2192156A1 (es) 2003-09-16
ATE299369T1 (de) 2005-07-15
AR025110A1 (es) 2002-11-06
JP2003506484A (ja) 2003-02-18
DE60021266T2 (de) 2006-05-24
GB0202908D0 (en) 2002-03-27
BR0013017A (pt) 2002-04-16
AU6635400A (en) 2001-03-13
IL147777A0 (en) 2002-08-14

Similar Documents

Publication Publication Date Title
DE60021266D1 (de) Verwendungen von zusammensetzungen zur behandlung oder vermeidung von schlafstörungen mit sehr niedrigdosierten cyclobenzaprine
DE60114580D1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
EP1274444A4 (de) Arzneistoffe zur behandlung psychiatrischer oder abusus-bedingter störungen
DE60109589D1 (de) Pharmazeutische zusammensetzung zur behandlung von akutem schmerz, chronischem schmerz und/oder neuropathischem schmerz und migräne
ATE446097T1 (de) Verwendung von uridin in kombination mit cholin zur behandlung von gedächtnisstörungen
DE59601624D1 (de) Verwendung von 2-amino-4-(4-fluorbenzylamino)-1-ethoxycarbonylaminobenzen zur prophylaxe und behandlung der folgen der akuten und chronischen zerebralen minderdurchblutung sowie neurodegenerativer erkrankungen
DE122006000035I1 (de) D2-Agonist enthaltendes transdermales Therapeutisches System zur Behandlung des Parkinson-syndroms und Berfahren zu seiner Herstellung
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
ATE265857T1 (de) Pharmazeutische oder diätetische zusammensetzung zur prävention oder behandlung von hyperoxalurie
DE60142590D1 (de) Verwendung von Botulinum Toxin zur Behandlung von post-operative Schmerzen
DE69936335D1 (de) Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen
DE10082139T1 (de) Zusammensetzung zur Behandlung von Reibungspaaren
DE69806801D1 (de) Galenische präparation zur prävention und behandlung von hepatokarzinomen
EP1191941A4 (de) Methode der prophylaxe und/oder behandlung von erkrankungen
EP1043983A4 (de) Tetracycline und/oder tetracyclinderivate zur behandlung und prophylaxe von cerebrovascularen krankheiten des nervensystems
PL357674A1 (pl) Kompozycje i sposoby leczenia zaburzeń związanychz hiperlipidemią
ATE390474T1 (de) Verwendung von polymerem material zur behandlung harter oberflächen
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
ATE237341T1 (de) Zusammensetzung zur vorbeugung und/oder behandlung von kreislaufstörungen, enthaltend l- carnitin derivate und ginkgo biloba extrakte
DE69825319D1 (de) Präparat zur vorbeugung und behandlung von entzündungen
DE69925578D1 (de) Pharmazeutische zusammenstellung zur vorbeugung und behandlung von mit zellkrankheiten des augenhintergrundes zusammenhängenden krankheiten
ATE234617T1 (de) Verwendung des saredutant und seiner pharmazeutisch akzeptablen salze zur behandlung von schwere depression
DE60018591D1 (de) Milchsäurebakterien zur behandlung und prophylaxe von giardiasis
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
DE60117122D1 (de) Verwendung von mirtazapin zur behandlung von schlafstörungen

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: L&L TECHNOLOGIES,LLC, NEW YORK, US

8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: KRELE PHARMACEUTICALS, INC. (N.D.GES.D. STAATE, US